🚨Our March issue is LIVE🚨 Learn about immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics in our cover profile🔷 Sourcing, nurturing, and retaining talent🔷Making HCP analytics actually work for commercial teams🔷and much more right

🚨Daily Exec Briefing 🚨 New FDA guidance signals a major shift for CAR-T development, calling for randomized trials with standard-of-care control groups and clear evidence of superiority over existing therapies. Link:

🚨Daily Exec Briefing🚨 Jaypirca matched response rates for Imbruvica with potentially improved survival in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Link:

Pharma needs AI that understands culture, compliance, and brand voice. Fine-tuned models help teams move faster with more accurate, trusted content. Read the partner perspective: https://t.co/D4i37NCnsj #PharmaMarketing #AIinHealthcare

🚨Daily Exec Briefing🚨 A successful transition from clinical development to commercial launch in cell and gene therapy requires early, structured collaboration with health systems to address operational, financial, and workflow challenges. Link:

🚨Daily Exec Briefing🚨 FDA’s approval of Breyanzi as the first CAR T therapy for relapsed or refractory marginal zone lymphoma underscores the therapy’s expanding leadership in B-cell malignancies, backed by compelling Phase II data Link:

🚨Daily Exec Briefing🚨 FDA names a new acting director of CDER and a new head of its Office of Nonprescription Drugs. Link:

🚨Daily Exec Briefing🚨 The agency says that its decision aims to improve employee workflow and build on its previously implemented generative AI tool Elsa. https://t.co/A20h5tjhZ6

Success Guide – Marketing’s Final Mile Explore how pharma marketers can bridge the gap between brand strategy and field execution to drive HCP engagement, compliance, and ROI.  Get the Guide: https://t.co/qusplTFLkE

Global gold ETFs kept the momentum going in November with US$5.2bn in inflows, that’s six months of inflows in a row. Learn more in our latest commentary on gold ETFs.

DTP is redefining access by giving every patient clarity, choice, and real-time control—far beyond what traditional hubs offer. See who benefits most and why it matters now. Read partner perspective: https://t.co/XIG0bgy6Hk #PatientAccess #HealthInnovation

🚨Daily Exec Briefing 🚨 The price adjustment to the popular GLP-1 agonist is part of an ongoing effort to expand access to patients with obesity by making medicines more affordable. Link:

🚨Daily Exec Briefing🚨 Moderna secures a $1.5 billion loan to enhance financial flexibility while targeting a 10% revenue growth by 2026, focusing on innovative mRNA therapies. Link:

🚨Daily Exec Briefing 🚨 As affordability, access, and transparency reshape U.S. healthcare, manufacturers are rapidly redefining direct-to-patient drug distribution as a core strategic capability. Link:

🚨Daily Exec Briefing🚨 The FDA approves multiple new drugs, enhancing treatment options for cancer and other conditions. Link:

🚨Daily Exec Briefing🚨 Johnson & Johnson aims to enhance its oncology portfolio and innovate prostate cancer treatments by expanding its therapeutic pipeline through the acquisition. Link:

Pharma’s next power move: Direct-to-Patient care. As patients demand speed + transparency, DTP models are redefining access, adherence, and trust. Learn how pharma can lead the next era of patient-centered care. Read the article: https://t.co/3INZgQj4Lo #PharmaInnovation

🚨Daily Exec Breifing🚨 How the Metsera deal extends Pfizer’s 25-year blueprint for growth. Link:

🚨Daily Exec Briefing 🚨 AstraZeneca's stock increased after positive Q3 earnings and deals with the Trump administration. Link:

Success Guide – First Contact to Field Excellence in Pharma  Learn how pharma leaders are using coaching to boost field performance, reinforce compliance, and deliver better HCP and patient outcomes - from onboarding to autonomy.  Explore the Guide: https://t.co/8jFTygLV8Z

🚨Daily Exec Briefing🚨 GLP-1 medications will be available on TrumpRx for discounted rates. Link:

🚨 Daily Exec Briefing🚨 Following Pfizer's lawsuits, Novo Nordisk enhanced its acquisition offer for Metsera. Link: https://t.co/SEYYh6V1nZ